Exosomal ncRNAs: Multifunctional contributors to the immunosuppressive tumor microenvironment of hepatocellular carcinoma

Huang, Qi; Zhong, Xin; Li, Jing; Hu, Rui; Yi, Jinyu; Sun, Jialing; Xu, Youhua; Zhou, Xiaozhou

doi:10.1016/j.biopha.2024.116409

Cited by 2 publications

(1 citation statement)

References 212 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CAFs are significant components of the tumor stroma and are primarily distributed in the perivascular or tumor peripheral fibrous mesenchyme ( 28 , 29 ). CAFs produce cytokines, ECM components, and associated enzymes ( 30 , 31 ).…”

Section: Overview Of the Tmementioning

confidence: 99%

Recent advances in understanding the immune microenvironment in ovarian cancer

Chen,

Yang,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

The occurrence of ovarian cancer (OC) is a major factor in women’s mortality rates. Despite progress in medical treatments, like new drugs targeting homologous recombination deficiency, survival rates for OC patients are still not ideal. The tumor microenvironment (TME) includes cancer cells, fibroblasts linked to cancer (CAFs), immune-inflammatory cells, and the substances these cells secrete, along with non-cellular components in the extracellular matrix (ECM). First, the TME mainly plays a role in inhibiting tumor growth and protecting normal cell survival. As tumors progress, the TME gradually becomes a place to promote tumor cell progression. Immune cells in the TME have attracted much attention as targets for immunotherapy. Immune checkpoint inhibitor (ICI) therapy has the potential to regulate the TME, suppressing factors that facilitate tumor advancement, reactivating immune cells, managing tumor growth, and extending the survival of patients with advanced cancer. This review presents an outline of current studies on the distinct cellular elements within the OC TME, detailing their main functions and possible signaling pathways. Additionally, we examine immunotherapy rechallenge in OC, with a specific emphasis on the biological reasons behind resistance to ICIs.

show abstract

Section: Overview Of the Tmementioning

confidence: 99%

Recent advances in understanding the immune microenvironment in ovarian cancer

Chen,

Yang,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

High-throughput screening for optimizing adoptive T cell therapies

Zhang,

Xu,

Gao

et al. 2024

Exp Hematol Oncol

View full text Add to dashboard Cite

Adoptive T cell therapy is a pivotal strategy in cancer immunotherapy, demonstrating potent clinical efficacy. However, its limited durability often results in primary resistance. High-throughput screening technologies, which include both genetic and non-genetic approaches, facilitate the optimization of adoptive T cell therapies by enabling the selection of biologically significant targets or substances from extensive libraries. In this review, we examine advancements in high-throughput screening technologies and their applications in adoptive T cell therapies. We highlight the use of genetic screening for T cells, tumor cells, and other promising combination strategies, and elucidate the role of non-genetic screening in identifying small molecules and targeted delivery systems relevant to adoptive T cell therapies, providing guidance for future research and clinical applications.

show abstract

Exosomal ncRNAs: Multifunctional contributors to the immunosuppressive tumor microenvironment of hepatocellular carcinoma

Cited by 2 publications

References 212 publications

Recent advances in understanding the immune microenvironment in ovarian cancer

Recent advances in understanding the immune microenvironment in ovarian cancer

High-throughput screening for optimizing adoptive T cell therapies

Contact Info

Product

Resources

About